Bexorg, born from Yale neuroscience research, has pioneered whole-brain perfusion technology—BrainEx—that keeps isolated human and pig brains metabolically active for days using artificial blood, intact circulation, and suppressed neuronal firing. This breakthrough platform transforms brains into “discovery machines,” enabling real-time tracking of transcriptomic, proteomic, metabolic, and biomarker responses at scale, powered by AI through its XO Digital system. With over 800 experimental runs and strong validation in high-impact journals like Nature, Bexorg provides pharma partners (e.g., Biohaven) detailed insights on drug distribution, mechanism of action, target engagement, and CNS biomarker identification—all using fully human tissue in a controlled, ethical environment.